News | February 09, 2024
Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
The registered capital of the newly founded company is € 50 million
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Collaboration streamlines patient access to oncology clinical trials
This turn valve is considered revolutionary because it supports back-to-back drug infusion through the same device
Inducts advanced AI-Powered 24x7 remote patient monitoring system
Subscribe To Our Newsletter & Stay Updated
